Testosterone Science

Research Summaries

Testosterone, Testosterone Replacement Therapy, and Cardiovascular Disease: A Contemporary Review

Population: Men

Citation

Testosterone, Testosterone Replacement Therapy, and Cardiovascular Disease: A Contemporary Review

Maligireddy AR, Barua ST, Barua RS.

J Am Heart Assoc. 2026;15(21):e054307. Published November 3, 2026.

PMID: 42924843 DOI: 10.1161/JAHA.126.054307

Study at a Glance

Design
Narrative review
Sources searched
MEDLINE; tables of contents of major cardiology, endocrinology, and urology journals; hand-searched reference lists; primary regulatory documents from the US Food and Drug Administration (FDA), the US Department of Health and Human Services (HHS), and the European Medicines Agency (EMA); and FDA-approved product labeling.

Question Addressed

The review asks how the cardiovascular risk of testosterone replacement therapy (TRT) should be classified after the TRAVERSE cardiovascular outcomes trial and the 2025 to 2026 US labeling actions, and how the evolving label should be read against the evidence that informs it. The authors addressed 5 subsidiary questions: whether low endogenous testosterone is a causal cardiovascular risk factor or a marker of multimorbidity; whether physiologic TRT alters the risk of atherosclerosis, arrhythmia, venous thromboembolism (VTE), or death; whether the adverse signals reported with TRT represent early-window effects, chance findings, or plausible harms; whether risk differs by formulation; and whether the short-to-medium-term noninferiority shown in TRAVERSE can be applied to the long-term exposure typical of clinical practice.

Plain Language Summary

This review looked at 2 questions: whether low testosterone causes heart disease, and whether testosterone treatment is safe for the heart. The authors graded each conclusion by how certain the evidence is.

Men with very low testosterone die earlier than men with normal levels [21]. However, low testosterone often reflects other health problems, such as obesity, diabetes, or chronic illness, so it is more likely a sign of poor overall health than a direct cause of heart disease [20].

The largest trial, TRAVERSE, followed 5246 men with low testosterone and high heart risk for about 3 years. Men using testosterone gel did not have more heart attacks, strokes, or cardiovascular deaths than men using a placebo gel [10]. Earlier and later analyses that combined many trials reached similar conclusions [4,9]. Some other problems were more common with testosterone, including an irregular heart rhythm called atrial fibrillation, blood clots in the lungs, sudden kidney injury [10], and bone fractures [14]. Of these, only the kidney finding has been seen again in a separate study [8]. All testosterone products raise blood pressure slightly [16].

The authors note that the trial tested only a gel, only for about 3 years, and that many men stopped treatment early. Testosterone should not be taken to protect the heart. In 2026, US health authorities proposed allowing wider use in older men with age-related decline in testosterone [15], a group in which long-term heart safety has not been tested. Treatment should be reserved for men with symptoms and confirmed low levels on repeated morning blood tests [3], with regular checks of blood pressure, red blood cell count, and heart rhythm.

Methods

The authors searched MEDLINE and journal tables of contents using combinations of the terms testosterone, hypogonadism, cardiovascular, major adverse cardiovascular events (MACE), atrial fibrillation (AF), VTE, fracture, hypertension, and coronary plaque. Searches were last updated in July 2026 and were supplemented by review of regulatory documents and FDA-approved labeling. Outcome-powered randomized controlled trials (RCTs), adequately adjusted observational analyses with prespecified and adjudicated end points, and individual participant data (IPD) meta-analyses were given priority.

The review separates 3 exposure states that carry different biology and risk: endogenous testosterone as an observed trait, physiologic replacement titrated to the midnormal range in men with confirmed deficiency, and supraphysiologic androgen exposure. Evidence from one state was not transferred to the others. Randomized, observational, imaging, and mechanistic data were mapped onto a single certainty scale:

  • Moderate certainty: For a therapeutic effect, at least 1 adequately powered RCT with adjudicated, prespecified end points, or a low-risk-of-bias meta-analysis of such trials with a consistent direction of effect. For an association, multiple large, independent, adequately adjusted cohorts concordant in direction and approximate magnitude, supported where available by IPD meta-analysis using mass spectrometry.
  • Low certainty: Unadjudicated or non-multiplicity-adjusted secondary randomized end points, observational data with important residual confounding or outcome misclassification, or randomized data that are directionally inconsistent.
  • Very low certainty: Sparse, heterogeneous, cross-sectional, surrogate, or mechanistic-imaging data, or single small studies with unmeasured major confounders; regarded as hypothesis generating.

Where a moderate rating rested on observational data, it applied to the existence and direction of an association only; the corresponding causal claim was rated lower and stated separately. Secondary and exploratory end points were treated as low- or very-low-certainty signals regardless of mechanistic plausibility.

Key Findings

Endogenous Testosterone and Cardiovascular Outcomes

  • All-cause mortality: Low total testosterone was associated with higher all-cause mortality across more than 15 independent cohorts (for example, adjusted hazard ratio [HR] 1.88; 95% CI 1.34–2.63 among 858 male veterans). An IPD meta-analysis restricted to mass-spectrometry assays (9 cohorts; 255,830 participant-years) found that risk rose below approximately 7.4 nmol/L (213 ng/dL) for all-cause mortality and below 5.3 nmol/L (153 ng/dL) for cardiovascular mortality (Yeap et al. 2024). The authors rated the association as moderate certainty and the causal claim as very low; cardiovascular mortality was rated low because of cause-of-death misclassification. The thresholds apply to mass-spectrometry results only and are not treatment thresholds.
  • Nonfatal myocardial infarction (MI) and stroke: Associations were weak and inconsistent. In 2416 men in MrOS Sweden, the highest testosterone quartile had a lower 5-year cardiovascular event risk (HR 0.70; 95% CI 0.56–0.88), whereas pooled IPD estimates frequently crossed unity. Rated low to very low certainty.
  • Atrial fibrillation: Cohort findings were directionally inconsistent. Higher testosterone was associated with more AF in ARIC (HR 1.33; 95% CI 1.07–1.66, highest vs lowest quartile) and ASPREE (quintile 5 vs 3: HR 1.98; 95% CI 1.33–2.94), whereas lower testosterone was associated with more AF in Framingham, most strongly in men aged 80 years or older (HR 3.53 per 1-SD decrease; 95% CI 1.96–6.37). In UK Biobank (173,498 men; 11,368 AF events), risk was modestly higher at both extremes. The authors interpret this as a U-shaped exposure-response relationship (low certainty) (Maligireddy et al. 2026).
  • Heart failure and subclinical atherosclerosis: Low testosterone was associated with worse functional status and higher mortality in heart failure and with more subclinical atherosclerosis in cross-sectional studies. The authors consider reverse causation and adiposity the most likely explanations (very low certainty).

Testosterone Therapy Before TRAVERSE

  • Early harm signals: The Testosterone in Older Men with Mobility Limitations (TOM) trial was stopped early after 23 cardiovascular-related adverse events with testosterone versus 5 with placebo among 209 frail older men (Basaria et al. 2010). After a published erratum, a 2013 Veterans Affairs analysis showed 3-year event rates of 25.7% versus 19.9% (absolute difference 5.8%; 95% CI −1.4% to 13.1%), which no longer supports its original conclusion (Vigen et al. 2013). A 2013 meta-analysis of 27 trials not designed for cardiovascular end points reported an odds ratio (OR) of 1.54 (95% CI 1.09–2.18) (Xu et al. 2013).
  • Observational benefit signals: Large cohorts reported lower mortality or fewer cardiovascular events with TRT, including an Ontario cohort (mortality HR 0.88; 95% CI 0.84–0.93) (Wallis et al. 2016), a Kaiser Permanente cohort (composite cardiovascular HR 0.67; 95% CI 0.62–0.73) (Cheetham et al. 2017), and a Veterans Affairs cohort of 83,010 men in whom testosterone normalization was associated with lower all-cause mortality (HR 0.44; 95% CI 0.42–0.46) (Sharma et al. 2015).
  • Randomized synthesis: The TestES IPD meta-analysis (35 trials; 5601 participants; mean duration 9.5 months) found no excess in cardiovascular events (OR 1.07; 95% CI 0.81–1.42) or deaths (OR 0.46; 95% CI 0.17–1.24) (Hudson et al. 2022).

TRAVERSE and Post-TRAVERSE Evidence

  • Primary end point: In 5246 men aged 45 to 80 years with symptomatic hypogonadism and established or high cardiovascular risk, transdermal 1.62% testosterone gel was noninferior to placebo for 3-point MACE (7.0% vs 7.3%; HR 0.96; 95% CI 0.78–1.17; P<0.001 for noninferiority against a margin of 1.5). Mean treatment duration was 21.7 months within a mean follow-up of 33.0 months (Lincoff et al. 2023). The authors rated this moderate certainty for the short-to-medium term.
  • Interpretation of noninferiority: The upper confidence limit excludes a relative increase of more than approximately 17%. Approximately 61% of participants in both arms discontinued study drug, about 18% were lost to follow-up, and mean achieved testosterone lay near the lower bound of the 350 to 750 ng/dL target for much of the trial. The authors note that discontinuation biases a noninferiority comparison toward the null, while acknowledging that sensitivity analyses censoring events after discontinuation gave similar results (Lincoff et al. 2023).
  • Secondary and exploratory signals: New-onset AF (3.5% vs 2.4%), acute kidney injury (AKI) (2.3% vs 1.5%), and pulmonary embolism (0.9% vs 0.5%) were more frequent with testosterone (Lincoff et al. 2023). In the prespecified fracture substudy (n=5204), clinical fracture occurred in 3.50% versus 2.46% (HR 1.43; 95% CI 1.04–1.97) (Snyder et al. 2024). None of these end points was multiplicity-adjusted, and only AKI has been independently replicated (TriNetX relative risk [RR] 1.53; 95% CI 1.07–2.18) (Greenberg et al. 2024). Rated low certainty.
  • Pooled randomized data: A meta-analysis of 23 RCTs (9280 men) found no difference in all-cause mortality (RR 0.85; 95% CI 0.60–1.19), nonfatal MI (RR 0.94; 95% CI 0.69–1.28), or nonfatal stroke (RR 1.00; 95% CI 0.67–1.50), but a higher incidence of cardiac arrhythmias (RR 1.53; 95% CI 1.20–1.97) (Braga et al. 2025). The authors caution that TRAVERSE contributes most of the randomized person-time, so these estimates do not independently replicate the trial.
  • Coronary atherosclerosis: A 3-year trial in 308 men aged 60 years or older found no difference in carotid intima-media thickness or coronary artery calcium progression (Basaria et al. 2015). The coronary computed tomography angiography substudy of the Testosterone Trials found greater noncalcified plaque progression with testosterone over 12 months (estimated difference 41 mm³; 95% CI 14–67; P=0.003) among 138 men, with no MACE in either group (Budoff et al. 2017). Rated low certainty.
  • Long-term observational data: In a Scottish cohort of 440 testosterone-exposed and 136,051 unexposed men, exposure was associated with a 5-component MACE composite (unadjusted HR 1.54; 95% CI 1.18–2.00; adjusted HR 1.55; 95% CI 1.19–2.01) (Connelly et al. 2025). The exposed group had a higher baseline comorbidity burden, there were only 56 events, and the composite is not comparable with the TRAVERSE end point. Rated very low certainty.
  • Blood pressure: FDA-mandated 24-hour ambulatory blood pressure monitoring (ABPM) studies confirmed a class-wide increase in blood pressure (FDA 2025). Mean systolic increases were 1.9 mm Hg for transdermal 1.62% gel at 16 weeks, 1.7 mm Hg for 1 oral testosterone undecanoate product at 4 months, and 4.3 mm Hg for a second oral product at approximately 16 weeks. The authors conclude that the magnitude differs by product rather than by route of administration.
  • Heart failure: A meta-analysis of 7 small RCTs (140 men; New York Heart Association class II to III) showed an increase in peak oxygen consumption but no effect on death, rehospitalization, functional class, or ejection fraction (very low certainty for clinical outcomes).

Regulatory Sequence and Clinical Framework

  • February 2025: The FDA recommended adding TRAVERSE results to all testosterone labeling and removing language on increased cardiovascular risk from the Boxed Warning, while retaining the limitation of use (LoU) for age-related hypogonadism. On the basis of the ABPM studies, the FDA required new blood pressure labeling (FDA 2025). The Boxed Warning itself remains, as it also addresses secondary exposure and abuse and dependence.
  • December 2025 to June 2026: An FDA expert panel supported broader eligibility, and on June 18, 2026, HHS, through the FDA, requested removal of the age-related hypogonadism LoU, narrowing of the prostate cancer contraindication to metastatic disease, and revision of the benign prostatic hyperplasia warning (HHS 2026). These are requests to sponsors and were not finalized at the time of writing.
  • 8-step decision framework: Clinical suspicion based on compatible symptoms; confirmation with at least 2 morning fasting total testosterone values below 10.4 nmol/L (300 ng/dL), preferably by liquid chromatography–tandem mass spectrometry; treatment of reversible causes first; assessment of cardiovascular contraindications (deferral for 3 to 6 months after MI, stroke, or revascularization; avoidance or specialist input with prior unprovoked VTE, thrombophilia, or class III to IV heart failure); shared decision-making; initiation with transdermal gel as a precautionary preference in men at moderate to high cardiovascular risk, titrated to 12.1 to 26.0 nmol/L (350 to 750 ng/dL); monitoring of testosterone, hematocrit, and blood pressure at 3, 6, and 12 months and annually thereafter; and explicit action thresholds (hematocrit above 54%, sustained systolic rise above 5 mm Hg on 2 visits, and a prostate-specific antigen rise above 1.4 ng/mL within 12 months).

Limitations and Strengths Affecting Interpretation

Strengths

  • Explicit certainty framework: A prespecified 3-tier rating separates associational from causal claims, and every recommendation in the clinical framework is labeled with the tier that supports it.
  • Detailed appraisal of TRAVERSE: The review examines the noninferiority margin, the approximately 61% discontinuation rate, loss to follow-up, achieved testosterone concentrations, and the difference between intention-to-treat and on-treatment estimates (Lincoff et al. 2023).
  • Correction of a frequently cited estimate: The review reports the corrected results of an early Veterans Affairs analysis, whose absolute risk difference has a 95% CI that crosses zero (Vigen et al. 2013).
  • Like-for-like blood pressure comparison: Product comparisons are restricted to 24-hour ABPM data from the FDA-mandated program, and the TRAVERSE office measurement is kept separate (FDA 2025).
  • Current regulatory analysis: Primary FDA and HHS documents up to July 2026 are integrated with the clinical evidence (FDA 2025; HHS 2026).
  • Reappraisal of the authors’ own work: The authors reinterpret their earlier normalization studies against the randomized evidence (Sharma et al. 2015).
  • Transparent reporting: The review follows the Scale for the Assessment of Narrative Review Articles and states its search strategy, period, and grading criteria.

Limitations

  • Narrative design: The search was limited to MEDLINE and English-language publications, and no formal risk-of-bias assessment or quantitative synthesis was performed.
  • Author-consensus grading: Certainty ratings are not a formal GRADE assessment, and several recommendations, including the 5 mm Hg blood pressure action threshold, are expert opinion.
  • Narrow randomized evidence base: Outcome data are limited to transdermal gel in middle-aged and older men, with approximately 3 years of follow-up (Lincoff et al. 2023).
  • Unconfirmed secondary signals: The findings for AF, AKI, pulmonary embolism, and fracture were not adjusted for multiplicity, and only AKI has been independently replicated (Greenberg et al. 2024; Lincoff et al. 2023; Snyder et al. 2024).
  • Pooled analyses not independent: Recent meta-analyses of randomized data are dominated by TRAVERSE and do not provide separate confirmation (Braga et al. 2025).
  • Observational confounding: Cohort studies reporting both benefit and harm are subject to confounding by indication, healthy-adherer bias, and residual confounding by comorbidity (Cheetham et al. 2017; Connelly et al. 2025; Sharma et al. 2015; Wallis et al. 2016).
  • Regulatory status: The June 2026 labeling changes were requests to sponsors and had not been finalized at the time of writing (HHS 2026).
  • Potential interpretive bias: Several of the observational normalization studies discussed were conducted by the authors’ group, although this is disclosed and addressed directly (Sharma et al. 2015).

Read this review as an evidence-graded account of the cardiovascular safety of physiologic transdermal TRT over approximately 3 years in men with confirmed hypogonadism and elevated cardiovascular risk. Decisions about long-term therapy, nontransdermal formulations, or men with age-associated low testosterone require outcome trials conducted in those populations.

Authors' Conclusions

The authors concluded that low endogenous testosterone should be regarded as a marker of multimorbidity and adverse metabolic status rather than a proven independent cause of cardiovascular disease. It is strongly associated with mortality at low concentrations, weakly and inconsistently associated with nonfatal events, and related to AF in a pattern better described as U-shaped. They concluded that physiologic transdermal TRT does not increase MACE over approximately 3 years in men with confirmed hypogonadism and elevated cardiovascular risk, but that this noninferiority result does not establish long-term clinical equivalence, does not demonstrate cardioprotection, and does not apply to other formulations. They view the 2025 to 2026 US regulatory steps as acknowledging medium-term MACE noninferiority while strengthening blood pressure labeling and proposing to extend licensed use to a population with limited outcome data. Safe use of TRT, in their view, depends on careful patient selection, distinction between pathologic hypogonadism and functional or age-associated low testosterone, and multidisciplinary care.

Commentary

Concern about the cardiovascular safety of TRT first came from studies that were not designed to assess adjudicated cardiovascular outcomes. A small RCT in 209 frail older men with mobility limitation was stopped early after 23 cardiovascular-related adverse events in the testosterone group, compared with 5 in the placebo group (Basaria et al. 2010). A Veterans Affairs cohort of men who had undergone coronary angiography reported more deaths, MIs, and strokes with testosterone. However, its corrected 3-year estimates showed an absolute risk difference of 5.8% with a 95% CI of −1.4% to 13.1% (Vigen et al. 2013). A meta-analysis of 27 placebo-controlled trials reported an OR of 1.54 (95% CI 1.09–2.18) for cardiovascular-related events, and the effect differed by source of funding (Xu et al. 2013). Large observational cohorts pointed in the opposite direction. In an Ontario cohort, the association depended on exposure duration: mortality was higher in the lowest exposure tertile (HR 1.11; 95% CI 1.03–1.20) and lower in the highest (HR 0.67; 95% CI 0.62–0.73) (Wallis et al. 2016). In a Kaiser Permanente cohort, TRT was associated with a lower composite cardiovascular risk (HR 0.67; 95% CI 0.62–0.73) (Cheetham et al. 2017). In the Veterans Affairs system, normalization of testosterone was associated with lower all-cause mortality (HR 0.44; 95% CI 0.42–0.46) (Sharma et al. 2015). The review explains why neither body of evidence was sufficient, on its own, to support regulatory or clinical decisions.

The randomized evidence reproduced neither the early harm signal nor the large observational benefit. The TestES IPD meta-analysis found no excess in cardiovascular events (OR 1.07; 95% CI 0.81–1.42) over a mean of 9.5 months (Hudson et al. 2022), and TRAVERSE showed noninferiority for 3-point MACE (HR 0.96; 95% CI 0.78–1.17) (Lincoff et al. 2023). A meta-analysis of 23 RCTs in 9280 men found no difference in all-cause mortality (RR 0.85; 95% CI 0.60–1.19), cardiovascular mortality (RR 0.85; 95% CI 0.65–1.12), MI, or stroke (Braga et al. 2025). The review confirms this randomized position and extends it in 2 ways. First, it shows that TRAVERSE contributes most of the randomized person-time to recent pooled analyses, so these analyses add precision but do not independently replicate the trial (Braga et al. 2025; Lincoff et al. 2023). Second, it reinterprets the authors’ own Veterans Affairs normalization data (Sharma et al. 2015) as more consistent with healthy-adherer and treatment-responder effects than with a direct cardioprotective effect. For endogenous testosterone, the review agrees with the IPD meta-analysis showing that mortality risk rises mainly below 7.4 nmol/L (213 ng/dL) (Yeap et al. 2024). It also agrees with a 2026 narrative review concluding that further studies are needed to confirm long-term cardiovascular safety (Yeap and Anawalt 2026).

The main difference from some expert bodies concerns how much reassurance the randomized data support. The Androgen Society has stated that an increased risk of MI, stroke, or cardiovascular death has been conclusively excluded (Morgentaler et al. 2024). The European Expert Panel for Testosterone Research considers TRT safe from a cardiovascular standpoint in appropriately selected and monitored patients (Zitzmann et al. 2026). This review takes an intermediate position because of the secondary and exploratory findings. In TRAVERSE, AF (3.5% vs 2.4%), AKI (2.3% vs 1.5%), and pulmonary embolism (0.9% vs 0.5%) were more frequent with testosterone (Lincoff et al. 2023), and clinical fracture was more frequent in the fracture substudy (HR 1.43; 95% CI 1.04–1.97) (Snyder et al. 2024). A propensity-matched TriNetX analysis replicated the AKI finding (RR 1.53; 95% CI 1.07–2.18) but did not show a statistically significant increase in AF (RR 1.48; 95% CI 0.93–2.37) (Greenberg et al. 2024). Because the point estimate is similar to that in TRAVERSE, the review considers this AF result underpowered rather than contradictory. The excess in cardiac arrhythmias in pooled randomized data (RR 1.53; 95% CI 1.20–1.97) (Braga et al. 2025) and the U-shaped relationship between endogenous testosterone and AF described by the same authors (Maligireddy et al. 2026) support continued surveillance. The only substantial long-term observational dataset is a Scottish cohort, which reported an adjusted HR of 1.55 (95% CI 1.19–2.01) for a 5-component MACE composite (Connelly et al. 2025). The review rates it very low certainty because of baseline imbalance and the small exposed group, but the investigators also concluded that longer-term data are needed (Connelly et al. 2025).

Imaging studies add to this uncertainty. A 3-year RCT in 308 men aged 60 years or older found no difference in carotid intima-media thickness or coronary artery calcium progression. Its investigators stated that the result should not be interpreted as establishing cardiovascular safety (Basaria et al. 2015). By contrast, the coronary computed tomography angiography substudy of the Testosterone Trials found greater progression of noncalcified plaque volume over 12 months (estimated difference 41 mm³; 95% CI 14–67) (Budoff et al. 2017). Atherosclerosis develops over years, which matters here because mean treatment duration in TRAVERSE was 21.7 months (Lincoff et al. 2023).

For clinicians, the most useful feature of the review is that each recommendation is tied to its level of evidence. Diagnosis should be limited to men with consistent symptoms and repeatedly low morning fasting testosterone, as the Endocrine Society recommends (Bhasin et al. 2018). Treatment should be deferred after a recent MI or stroke and avoided in men with thrombophilia, in line with guideline contraindications (Bhasin et al. 2018). Blood pressure should be measured before and during therapy, because the ABPM program confirmed a class-wide increase (FDA 2025). Renal function needs attention in men with chronic kidney disease and in those taking renin-angiotensin-aldosterone system inhibitors or diuretics, given the replicated AKI signal (Greenberg et al. 2024; Lincoff et al. 2023). Hematocrit, heart rhythm, and symptoms of VTE should be monitored, particularly in the first months of therapy (Lincoff et al. 2023). Preferring transdermal gel in men at moderate to high cardiovascular risk is a precaution and not a demonstrated safety advantage: gel is simply the only formulation with adjudicated outcome data (Lincoff et al. 2023). TRT should not be presented as cardioprotective, since randomized data show no reduction in mortality or MACE (Braga et al. 2025; Lincoff et al. 2023).

The review is directly relevant to current US regulatory activity. The February 2025 class-wide labeling changes removed cardiovascular risk language from the Boxed Warning, retained the LoU for age-related hypogonadism, and added blood pressure warnings (FDA 2025). The June 2026 HHS request would remove that LoU, narrow the prostate cancer contraindication to metastatic disease, and revise the benign prostatic hyperplasia warning (HHS 2026). The Androgen Society and European panel positions are consistent with this direction (Morgentaler et al. 2024; Zitzmann et al. 2026). The Endocrine Society guideline, issued before TRAVERSE, reserves the diagnosis for men with symptoms and unequivocally low testosterone (Bhasin et al. 2018). The review points out that men with age-associated low testosterone have the least outcome-trial evidence and the most potentially reversible causes. For medical affairs and regulatory professionals, this distinction matters when describing the evidence behind the proposed label language. The TRAVERSE result applies to the population, formulation, and treatment duration studied (Lincoff et al. 2023), and the blood pressure warnings remain in place separately from the cardiovascular language that was removed (FDA 2025).

This review should be read as a structured, evidence-graded appraisal. It shows that physiologic transdermal TRT has reassuring short-to-medium-term MACE data in appropriately selected men, but that long-term safety, the safety of other formulations, and the significance of the secondary signals remain unestablished.

References

1. Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363(2):109-122.

DOI: PMID

PubMed: PMID

Supporting quote: “associated with an increased risk of cardiovascular adverse events.”

2. Basaria S, Harman SM, Travison TG, Hodis H, Tsitouras P, Budoff M, et al. Effects of testosterone administration for 3 years on subclinical atherosclerosis progression in older men with low or low-normal testosterone levels: a randomized clinical trial. JAMA. 2015;314(6):570-581.

DOI: PMID

PubMed: PMID

Supporting quote: “should not be interpreted as establishing cardiovascular safety of testosterone use in older men.”

3. Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744.

DOI: PMID

PubMed: PMID

Supporting quote: “We recommend confirming the diagnosis by repeating the measurement of morning fasting total T concentrations.”

4. Braga MAP, Rivera A, Marinheiro G, Felix N, Carvalho PEP, Gewehr DM, et al. Long-term cardiovascular safety of testosterone-replacement therapy in middle-aged and older men: a meta-analysis of randomized controlled trials. Am J Cardiovasc Drugs. 2025;25(6):767-777.

DOI: PMID

PubMed: PMID

Supporting quote: “TRT did not increase all-cause mortality, cardiovascular mortality, stroke, or myocardial infarction”

5. Budoff MJ, Ellenberg SS, Lewis CE, Mohler ER, Wenger NK, Bhasin S, et al. Testosterone treatment and coronary artery plaque volume in older men with low testosterone. JAMA. 2017;317(7):708-716.

DOI: PMID

PubMed: PMID

Supporting quote: “associated with a significantly greater increase in coronary artery noncalcified plaque volume”

6. Cheetham TC, An J, Jacobsen SJ, Niu F, Sidney S, Quesenberry CP, et al. Association of testosterone replacement with cardiovascular outcomes among men with androgen deficiency. JAMA Intern Med. 2017;177(4):491-499.

DOI: PMID

PubMed: PMID

Supporting quote: “dispensed testosterone prescriptions were associated with a lower risk of cardiovascular outcomes”

7. Connelly PJ, Owusu Achiaw S, Friday JM, Ho FK, Geue C, Padmanabhan S, et al. Association between long-term testosterone exposure and major adverse cardiovascular events in aging men. J Endocr Soc. 2025;9(11):bvaf156.

DOI: PMID

PubMed: PMID

Supporting quote: “long-term testosterone therapy was associated with increased CV risk.”

8. Greenberg DR, Kohn TP, Asanad K, Brannigan RE, Halpern JA. Association of testosterone replacement therapy with atrial fibrillation and acute kidney injury. J Sex Med. 2024;21(12):1201-1203.

DOI: PMID

PubMed: PMID

Supporting quote: “Kaplan-Meier survival analysis showed a significantly increased risk of AKI among men on TRT”

9. Hudson J, Cruickshank M, Quinton R, Aucott L, Aceves-Martins M, Gillies K, et al. Adverse cardiovascular events and mortality in men during testosterone treatment: an individual patient and aggregate data meta-analysis. Lancet Healthy Longev. 2022;3(6):e381-e393.

DOI: PMID

PubMed: PMID

Supporting quote: “no evidence that testosterone increased short-term to medium-term cardiovascular risks”

10. Lincoff AM, Bhasin S, Flevaris P, Mitchell LM, Basaria S, Boden WE, et al. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med. 2023;389(2):107-117.

DOI: PMID

PubMed: PMID

Supporting quote: “noninferior to placebo with respect to the incidence of major adverse cardiac events.”

11. Maligireddy AR, Barua ST, Barua RS. Association of testosterone and testosterone replacement therapy with atrial fibrillation: an updated review. J Endocr Soc. 2026;10(9):bvag180.

DOI: PMID

PubMed: PMID

Supporting quote: “Converging evidence thus supports a U-shaped T-AF relationship.”

12. Morgentaler A, Dhindsa S, Dobs AS, Hackett G, Jones TH, Kloner RA, et al. Androgen Society position paper on cardiovascular risk with testosterone therapy. Mayo Clin Proc. 2024;99:1785-1801.

DOI: PMID

PubMed: PMID

Supporting quote: “conclusively determined that TTh is not associated with increased risks of heart attack”

13. Sharma R, Oni OA, Gupta K, Chen G, Sharma M, Dawn B, et al. Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men. Eur Heart J. 2015;36(40):2706-2715.

DOI: PMID

PubMed: PMID

Supporting quote: “was associated with a significant reduction in all-cause mortality, MI, and stroke.”

14. Snyder PJ, Bauer DC, Ellenberg SS, Cauley JA, Buhr KA, Bhasin S, et al. Testosterone treatment and fractures in men with hypogonadism. N Engl J Med. 2024;390(3):203-211.

DOI: PMID

PubMed: PMID

Supporting quote: “The fracture incidence was numerically higher among men who received testosterone”

15. US Department of Health and Human Services (HHS). HHS announces requested updates to testosterone therapy product labels. Press release. June 18, 2026.

URL:

Supporting quote: “Remove the limitation of use stating that the safety and effectiveness of testosterone replacement therapy in men with age-related hypogonadism have not been established.”

16. US Food and Drug Administration (FDA). FDA issues class-wide labeling changes for testosterone products. Drug Safety and Availability. February 28, 2025.

URL:

Supporting quote: “Results from the completed ABPM studies confirmed an increase in blood pressure with use of all testosterone products, class-wide.”

17. Vigen R, O’Donnell CI, Barón AE, Grunwald GK, Maddox TM, Bradley SM, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310(17):1829-1836. Erratum in: JAMA. 2014;311(9):967.

DOI:

PubMed: PMID

Supporting quote: “with an absolute risk difference of 5.8% (95% CI, -1.4% to 13.1%) [corrected]”

18. Wallis CJ, Lo K, Lee Y, Krakowsky Y, Garbens A, Satkunasivam R, et al. Survival and cardiovascular events in men treated with testosterone replacement therapy: an intention-to-treat observational cohort study. Lancet Diabetes Endocrinol. 2016;4(6):498-506.

DOI: PMID

PubMed: PMID

Supporting quote: “those in the highest tertile of testosterone exposure had decreased risk of mortality”

19. Xu L, Freeman G, Cowling BJ, Schooling CM. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med. 2013;11:108.

DOI:

PubMed: PMID

Supporting quote: “The effects of testosterone on cardiovascular-related events varied with source of funding.”

20. Yeap BB, Anawalt BD. Endogenous testosterone, testosterone treatment, and cardiovascular health outcomes in men. J Clin Endocrinol Metab. 2026;111(2):e339-e351.

DOI: PMID

PubMed: PMID

Supporting quote: “additional studies are needed to confirm long-term cardiovascular safety”

21. Yeap BB, Marriott RJ, Dwivedi G, Adams RJ, Antonio L, Ballantyne CM, et al. Associations of testosterone and related hormones with all-cause and cardiovascular mortality and incident cardiovascular disease in men: individual participant data meta-analyses. Ann Intern Med. 2024;177(6):768-781.

DOI: PMID

PubMed: PMID

Supporting quote: “those with testosterone concentrations below 5.3 nmol/L (<153 ng/dL) had higher CVD mortality risk.”

22. Zitzmann M, Rastrelli G, Murray RD, Edwards D, Reisman Y, Rao PM, et al. Cardiovascular safety of testosterone therapy: insights from the TRAVERSE trial and beyond. A position statement of the European Expert Panel for Testosterone Research. Andrology. 2026;14(1):294-302.

DOI:

PubMed: PMID

Supporting quote: “when prescribed to appropriately selected patients and monitored regularly, is safe from a cardiovascular standpoint”

Study at a Glance

  • Design. Targeted narrative review, reported in accordance with the Scale for the Assessment of Narrative Review Articles (SANRA).
  • Period covered. English-language publications from January 2000 through July 2026.
  • Evidence grading method. Prespecified 3-tier structured author-consensus rating (moderate, low, and very low certainty), assigned independently by 2 authors and reconciled by discussion. The authors state that this is not a formal GRADE assessment.
  • Outputs. 4 evidence tables, 4 figures, and an 8-step clinical decision framework in which each recommendation is labeled with its certainty tier.

All Research Summaries

Post a Comment or Question

Shared Decision Making

Bring the Evidence to Your Next Consultation

Use our patient resources and questionnaires to prepare questions about symptoms, testing and treatment options for your doctor.